February 6th 2023
Zuranolone is a rapid-acting neuroactive steroid that can take effect in 14 days to treat patients with major depressive disorder and postpartum depression. The FDA has assigned a PDUFA action date of Aug. 5, 2023.
December 20th 2022
October 7th 2022
September 14th 2022
August 22nd 2022
Otsuka, Lundbeck Submit sNDA for Rexulti in Adolescents with SchizophreniaOctober 15th 2021
Submission is based on extrapolation analysis and results examining the effects of Rexulti in treating symptoms of schizophrenia in patients 13 to 17 years old. The FDA is expected to complete its review in December 2021.
Bouquets and Brickbats for FDA OK of Alzheimer's Drug AduhelmJune 15th 2021
The Alzheimer's Association praises the approval but not the price tag. A Harvard Medical School professor who resigned from an FDA advisory committee says the OK "was probably the worst approval decision in recent U.S. history" in his resignation letter.
Management of antipsychotic medication polypharmacyJune 13th 2013
Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
72nd American Diabetes Association Scientific Sessions: Clinical updates review findings on risk of malignancy with pioglitazone, as well as various risk factors associated with insulin glargine useAugust 1st 2012
A review of drug therapies and research presented at the 2012 Scientific Session of the American Diabetes Association.
American Psychiatric Association 2012 Annual Meeting: Clinical updates review findings on long-acting levomilnacipran in major depressive disorder, depot versus oral antipsychotics for schizophreniaJuly 1st 2012
A review of drug therapies and research presented at the 2012 Annual Meeting of the American Psychiatric Association
OIG report evaluates claims for atypical antipsychotic drugs prescribed to nursing home residentsMay 20th 2011
More than half of Medicare claims for atypical antipsychotic drugs are erroneous, amounting to $116 million, according to a 48-page report released May 4 by the Office of the Inspector General.
FDA warns of risks associated with the use of antipsychotic medications in pregnancyApril 1st 2011
FDA recently announced that the 'Pregnancy' sections of labeling for all antipsychotic medications will now have to include wording about the potential risk for extrapyramidal side effects and withdrawal symptoms in newborns whose mothers were treated with these drugs during the third trimester of pregnancy.
Brand-name, generic antidepressants share similar discontinuation rates and healthcare costs during 6 months of treatmentApril 1st 2011
Patients using brand-name or generic antidepressant medications to treat major depressive disorder have similar drug discontinuation rates and accrue comparable healthcare costs during the first 6 months of treatment, according to a study published in March 2011 in the Journal of Managed Care Pharmacy.
Guanfacine extended-release tablets (Intuniv): Selective alpha2a-adrenergic receptor agonist approved for the treatment of ADHDOctober 1st 2009
New formulation: Guanfacine extended-release tablets (Intuniv) were approved on September 2, 2009, for the treatment of attention-deficit/hyperactivity disorder (ADHD)
Second-generation antidepressants similar in efficacyDecember 1st 2008
Second-generation antidepressants generally have equivalent efficacy, according to a review published in the Annals of Internal Medicine. Although these agents demonstrate similar response rates, differences in onset of action or side effects may affect prescribing decisions.
Treatment with SSRIs or venlaxafine associated with increased risk of GI bleedingAugust 1st 2008
In a nested, case-control study published in the Archives of General Psychiatry, investigators observed that the use of selective serotonin-reuptake inhibitors (SSRIs) increased the risk of upper gastrointestinal (GI) tract bleeding; this increased risk was also observed with the serotonin and norepinephrine reuptake inhibitor (SNRI) venlafaxine. This risk may be increased when the agents are used concomitantly with nonsteroidal anti-inflammatory drugs (NSAIDs) and decreased when used concomitantly with acid-suppressing agents.
Iloperidone: A novel atypical antipsychotic for the treatment of schizophreniaJune 1st 2008
Iloperidone, a new-generation atypical antipsychotic, is currently under investigation for the treatment of schizophrenia. In 4 separate phase 3 trials, iloperidone has demonstrated efficacy in treating schizophrenia, with total Positive and Negative Symptom Scale (PANSS) scores decreasing by a range of 8 to 14 points depending on the iloperidone dose.